You just read:

Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting

News provided by

Xencor, Inc.

Nov 13, 2016, 09:00 ET